Abstract: Objective: To examine a polymorphism within the 3′ untranslated region of the Leukemia inhibitory factor gene for an association with multiple sclerosis within an Australian case-control population. Methods: A test group of 121 unrelated multiple sclerosis patients, of Caucasian origin, and 121 controls, matched for ethnicity, sex and age (+/-5 years) were included in the study. The LIF 3′ UTR StuI polymorphism was genotyped by restriction fragment length polymorphism analysis. Statistical analysis of genotype and allele frequencies included Hardy-Weinberg law and conventional contingency table analysis incorporating the standard chi-squared test for independence. Results: Allelic and genotype frequencies did not demonstrate a significant association between the case and control groups for the tested LIF 3′ UTR StuI polymorphism. Conclusion: The results indicate that the LIF 3′ UTR StuI polymorphism is not associated with multiple sclerosis, however we cannot exclude the hypothesis that other polymorphic alleles of LIF could be implicated in MS susceptibility. This manuscript describes an investigation of one polymorphisms, LIF C3951T in Multiple Sclerosis (MS) in a case-control study of an Australian Caucasian population. The MS population was compared with matched controls (gender, age, and ethnicity) using PCR and restriction enzyme techniques. Allele frequencies were compared using Chi-square based statistical analyses. We report that results from the present study do not support a role for the genetic variant in MS susceptibility. This manuscript has not been nor will be published in whole or in part by any other journal, and all listed authors concur with the submission.
Interestingly, RR-MS coincides with periods of remission, in which regeneration of the myelin is known to involve anti-inflammatory agents, neurotrophins and resident precursors of oligodendrocytes [1] .
Particular attention has been focused on the investigation of inflammatory molecules within the immune system. In the presence of myelin proteins, infiltrated leukocytes become reactive and secrete a plethora of pro-inflammatory agents degrading the myelin sheath [2] . All genome-wide screens in MS have revealed a global implication of the major histocompatibility complex (MHC) at the 6p21 chromosomal region [3] [4] [5] [6] [7] . Leukemia inhibitory factor (LIF) belongs to the neurotrophic family and is present in MS plaques [8] . The gene coding for LIF is located at 22q12.2, a region associated with MS in a Spanish population [9] . Macrophages and T cells secrete LIF and have been shown to confer oligodendrocyte protection in the CNS [8] . Experiments undertaken in the experimental allergic encephalomyelitis animal model of MS have
shown that the level of expression of LIF mRNA is up-regulated in plaques [10] .
Additionally, antibodies directly targeted to LIF and inhibiting LIF action showed increase severity in EAE mice [11] . The positive effect on oligodendrocytes appears to be mediated through LIF induced activation of suppressors of cytokine signalling (SOCS) [12] . SOCS have critical roles in regulating numerous cytokines that act through the janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway, creating a negative feedback loop that limits the effect of cytokine signalling on the cell [13] . The up-regulation of SOCS has been shown to ameliorate arthritis in mice, and possibly be a therapeutic strategy for treating the inflammatory disease [14, 15] . SOCS regulates an important cytokine interferon-γ (INFγ) which is widely implicated in MS lesions [16, 17] . In addition, LIF has opposite effects to the proinflammatory agent INFγ and has been demonstrated to block the cytotoxic effects of INFγ on oligodendrocytes [18] .
Interestingly, a polymorphism located within the 3′ untranslated region (UTR) of LIF has been shown to affect the level of stability of LIF mRNA [19] . This CT transition reduces stability of LIF mRNA and may potentially reduce the expression of LIF [19] . In this present report, we investigated the genotypes of an Australian MS population (n=121) age and sex matched with non neurological disease affected healthy controls (n=121) for the C T transition polymorphism of the LIF gene. Genomic DNA was extracted from peripheral blood leucocytes using a standard salting-out protocol as previously described [20] .
Methods
Genotyping. The CT polymorphism was genotyped with a restriction fragment length polymorphism (RFLP) used to detect each variant. The 3′ UTR of LIF was investigated using the StuI restriction enzyme to detect, at the nucleotide position 3951, a C to T transition. The polymorphic region was amplified by standard, unlabeled oligonucleotides followed by restriction enzyme digestion corresponding to the RFLP. Oligonucleotide primers used for the StuI RFLP were: forward primer 5′- During CNS inflammation, LIF is secreted by astrocytes [22] and acts on oligodendrocytes to prevent their loss and increase their survival [23, 24] .
Results

We could clearly determine the type of LIF
Furthermore, protective effects of LIF include roles in reducing cytotoxic activity of
INFγ, a pro-inflammatory molecule secreted by infiltrating T cells. Additionally, the Th1 to Th2 shift observed in MS remissions correlates with differences in LIF secretion levels between these types of cells [8] . Th2 cells show higher LIF concentrations compared to Th1 clones demonstrating a LIF Th2 mediated antiinflammatory effect. However, LIF neurotrophin has been shown to be reduced in RR-MS compared to controls [8] . Interestingly, Simvastatin, a cholesterol lowering drug with associated anti-inflammatory effects that may possibly be used in the future to treat MS [25] , has previously been shown to increase LIF level secretions from both CD4+ and CD8+ T cells [8] . Despite results implicating a role for LIF in MS,
our study could not demonstrate any association between the tested LIF functional variant and MS. Similarly, results of a recent Belgium study also showed no association for the C→T transition of LIF in MS [21] . We cannot however exclude the hypothesis that other polymorphic alleles of LIF could be implicated in MS susceptibility.
LIF acts on the LIF receptor (LIFR), a gene localised to 5p13, a region strongly associated with MS especially in Finnish populations [26] . Of note, recent studies from UK, Scandinavia, Belgium and USA revealed that interleukin 7 receptor alpha (IL7RA) also localised to 5p13 might be implicated in MS [21, 27, 28] . Association studies for LIFR have not yet been carried out and may be useful for determining whether LIFR plays a role in MS susceptibility.
